The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2015

Filed:

Oct. 30, 2012
Applicant:

Merck Patent Gmbh, Darmstadt, DE;

Inventors:

Werner Mederski, Zwingenberg, DE;

Thomas Fuchss, Bensheim-Auerbach, DE;

Ulrich Emde, Darmstadt, DE;

Hans-Peter Buchstaller, Griesheim, DE;

Assignee:

Merck Patent GmbH, Darmstadt, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/06 (2006.01); C07D 401/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 253/08 (2006.01); C07F 7/18 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); C07F 7/08 (2006.01); C07F 7/10 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); C07D 253/08 (2013.01); C07D 401/06 (2013.01); C07D 401/14 (2013.01); C07D 409/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07F 7/0812 (2013.01); C07F 7/10 (2013.01); C07F 7/1856 (2013.01); C07F 7/1868 (2013.01);
Abstract

The invention relates to compounds of the formula (I) in which R1, L and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumors, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into a salt thereof.


Find Patent Forward Citations

Loading…